<DOC>
	<DOCNO>NCT02207530</DOCNO>
	<brief_summary>Primary Objective : To assess efficacy MEDI4736 monotherapy term ORR</brief_summary>
	<brief_title>Phase II Study MEDI4736 Monotherapy Treatment Recurrent Metastatic Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>This phase II , multi-center , single-arm , global study MEDI4736 monotherapy patient PD-L1 positive recurrent metastatic Squamous Cell Carcinoma Head Neck ( SCCHN ) , progress treatment 1 systemic palliative regimen recurrent metastatic disease must contain platinum agent .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age ≥18 year Written inform consent obtain patient/legal representative Histologically confirm recurrent metastatic SCCHN Tumor progression recurrence treatment 1 systemic palliative regimen recurrent metastatic disease must contain platinum agent . Written consent provide newly acquire tumor tissue ( prefer ) archival tissue purpose establish PDL1 status . Confirmed PDL1positive SCCHN Ventana SP263 assay WHO/ECOG performance status 0 1 At least 1 measurable lesion baseline No prior exposure immunemediated therapy Adequate organ marrow function Evidence postmenopausal status negative urinary serum pregnancy test . Histologically confirm squamous cell carcinoma primary anatomic location head neck Received 1 systematic palliative regimen recurrent metastatic disease Any concurrent chemotherapy , Investigational Product , biologic , hormonal therapy cancer treatment Prior randomization treatment previous MEDI4736 and/or tremelimumab clinical study regardless treatment arm assignment receipt investigational anticancer therapy within 28 day 5 halflives Receipt last dose approve ( market ) anticancer therapy ( chemotherapy , target therapy , biologic therapy , mAbs , etc ) within 21 day prior first dose study treatment Major surgical procedure within 28 day prior first dose Investigational Product Any unresolved toxicity NCI CTCAE Grade ≥2 previous anticancer therapy exception alopecia , vitiligo , laboratory value define inclusion criterion Current prior use immunosuppressive medication within 14 day first dose MEDI4736 History allogeneic organ transplantation Active prior document autoimmune inflammatory disorder ; Uncontrolled intercurrent illness Another primary malignancy Patients history brain metastasis , spinal cord compression , leptomeningeal carcinomatosis History active primary immunodeficiency Known history previous tuberculosis Active infection include hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) Receipt live , attenuated vaccine within 30 day prior first dose MEDI4736 Pregnant breastfeed female patient Mean QT interval correct heart rate ( QTc ) ≥470 m calculate 3 electrocardiogram ( ECGs ) use Fridericia 's Correction Any condition , opinion Investigator , would interfere evaluation IP interpretation patient safety study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Head neck cancer ; SCCHN</keyword>
</DOC>